PharmaCyte Biotech IncNASDAQ PMCB Stock Report

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Laguna Hills, California and currently employs 4 full-time employees. The company went IPO on 2003-09-11. The firm is focused on developing and preparing to commercialize cellular therapies for cancer, diabetes and malignant ascites based upon its cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The company is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. The Cell-in-a-Box encapsulation technology enables genetically engineered live human cells to be used to produce various biologically active molecules. Its current generation of product candidates is referred to as CypCaps. The company is developing therapies for pancreatic and other solid cancerous tumours by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated, genetically modified insulin-producing cells. The firm is also developing therapies for cancer that involve prodrugs based upon certain constituents of the cannabis plant.